MedDataX Logo

Message Framing on Recruiting Rh-D Negative Blood Donors

NCT04484896 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1082

Last updated 2020-07-28

No results posted yet for this study

Summary

Rh negative blood group is a rare blood group in China, as it only accounts for 0.3-0.4 percent of the Han population. Therefore, low inventory is often found in blood collection and supply agencies in many regions in China. On July 22, 2020 blood stockpile of O-negative and A-negative in Guangzhou Blood Center reached the warning line, and we took measures for emergency recruitment. O-negative and A-negative blood donors whose last donation dates were between January 1, 2018 and December 31, 2019 were identified and randomly assigned to four groups. Three different recruitment text messages were send three groups. We observed the re-donation rates among four groups within one week.

Conditions

  • Blood Donation

Interventions

OTHER

Gain-framed SMS message

Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.

OTHER

Loss-framed SMS message

Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.

OTHER

Information SMS message

Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.

Sponsors & Collaborators

  • Guangzhou Blood Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-22
Primary Completion
2020-07-29
Completion
2020-07-30

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04484896 on ClinicalTrials.gov